COVID-19 Vaccination in Cancer Patients

Protective Benefits

The American Society of Clinical Oncology and other guideline societies frame COVID-19 vaccination as a protective measure against infection-related morbidity and mortality, not as an enhancement strategy for cancer treatment 1, 2, 3, 4
COVID-19 vaccination significantly reduces hospitalization and death within 30 days in cancer patients, with an odds ratio of 0.44 5
The benefit of COVID-19 vaccination is purely related to preventing severe COVID-19 illness, not improving cancer outcomes 5

The European Society for Medical Oncology notes that mRNA vaccine efficacy is 83% in solid tumors and only 72% in hematological malignancies 1, 2, 3, 4
Anti-CD20 therapies and cytotoxic chemotherapy significantly reduce antibody responses, according to the National Comprehensive Cancer Network 1, 2, 3

The National Comprehensive Cancer Network provides guidelines to avoid confounding adverse events, recommending vaccination on availability with no specific timing to enhance efficacy for patients on immune checkpoint inhibitors 7, 8, 9
Vaccination should be avoided on the same day as immunotherapy infusions during dose-limiting toxicity periods to distinguish adverse events, as suggested by the European Society for Medical Oncology 7, 8
For immunotherapy agents with cytokine-release syndrome risk, vaccination should be deferred until after the DLT window, according to the American Society of Clinical Oncology 7, 8

Patients on checkpoint inhibitors should be vaccinated on availability without expecting anti-tumor benefit, as recommended by the National Comprehensive Cancer Network 7, 8, 9
Vaccination should be timed to avoid same-day administration with immunotherapy infusions to distinguish side effects, according to the European Society for Medical Oncology 7, 8
Patients should be monitored for immune-related adverse events (IRAEs) in the 2-3 days following vaccination, as suggested by the American Society of Clinical Oncology 1, 2, 3
Additional booster doses should be considered in immunocompromised patients who fail to mount adequate responses, according to the Journal of Clinical Oncology 5